PCSK9阻害薬 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "PCSK9阻害薬" in Japanese language version.

refsWebsite

Global rank Japanese rank

4^th place

24^th place

2^nd place

6^th place

18^th place

107^th place

5^th place

19^th place

2fiercebiotech.com

low place

low place

7^th place

63^rd place

719^th place

3,311^th place

low place

low place

14^th place

320^th place

1corporate-ir.net

3,174^th place

3,306^th place

low place

low place

234^th place

363^rd place

archive.today

“Alnylam Reports Positive Preliminary Clinical Results for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia”. Press Release. BusinessWire (2011年1月4日). 2013年2月21日時点のオリジナルよりアーカイブ。2011年1月4日閲覧。

corporate-ir.net

phx.corporate-ir.net

“Alnylam Reports Positive Preliminary Clinical Results for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia”. Press Release. BusinessWire (2011年1月4日). 2013年2月21日時点のオリジナルよりアーカイブ。2011年1月4日閲覧。

doi.org

“PCSK9 Inhibitors: Economics and Policy”. Journal of the American College of Cardiology 70 (21): 2677–2687. (2017). doi:10.1016/j.jacc.2017.10.001. PMID 29169476.
“Biology of PCSK9: beyond LDL cholesterol lowering”. Cardiovascular Research 112 (1): 429–42. (August 2016). doi:10.1093/cvr/cvw194. PMC 5031950. PMID 27496869.
“Sequence variations in PCSK9, low LDL, and protection against coronary heart disease”. The New England Journal of Medicine 354 (12): 1264–72. (March 2006). doi:10.1056/NEJMoa054013. PMID 16554528.
“Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia”. Drug News Perspect. 21 (6): 323–30. (2008). doi:10.1358/dnp.2008.21.6.1246795. PMID 18836590.
“Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels”. Proc. Natl. Acad. Sci. U.S.A. 106 (24): 9546–7. (June 2009). Bibcode: 2009PNAS..106.9546S. doi:10.1073/pnas.0904560106. PMC 2701045. PMID 19506257.
“Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels”. J. Biol. Chem. 283 (46): 31791–801. (November 2008). doi:10.1074/jbc.M805971200. PMID 18799458.
Fitzgerald, Kevin; White, Suellen; Borodovsky, Anna; Bettencourt, Brian R.; Strahs, Andrew; Clausen, Valerie; Wijngaard, Peter; Horton, Jay D. et al. (2017). “A Highly Durable RNAi Therapeutic Inhibitor of PCSK9”. New England Journal of Medicine 376 (1): 41–51. doi:10.1056/NEJMoa1609243. ISSN 0028-4793. PMC 5778873. PMID 27959715.
“Phase 3 data for PCSK9 inhibitor wows”. Nature Biotechnology 31 (12): 1057–8. (December 2013). doi:10.1038/nbt1213-1057. PMID 24316621.
“New therapies for reducing low-density lipoprotein cholesterol”. Endocrinology and Metabolism Clinics of North America 43 (4): 1007–33. (December 2014). doi:10.1016/j.ecl.2014.08.008. PMID 25432394.
“PCSK9 inhibition: the next statin?”. Journal of the American College of Cardiology 59 (25): 2354–5. (June 2012). doi:10.1016/j.jacc.2012.03.011. PMID 22465426.
“Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis”. Annals of Internal Medicine 163 (1): 40–51. (July 2015). doi:10.7326/M14-2957. PMID 25915661.
“Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data”. Current Treatment Options in Cardiovascular Medicine 19 (8): 58. (August 2017). doi:10.1007/s11936-017-0556-0. PMID 28639183.
Schmidt, Amand F.; Carter, John-Paul L.; Pearce, Lucy S.; Wilkins, John T.; Overington, John P.; Hingorani, Aroon D.; Casas, J. P. (October 20, 2020). “PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease”. The Cochrane Database of Systematic Reviews 10 (12): CD011748. doi:10.1002/14651858.CD011748.pub3. ISSN 1469-493X. PMC 8094613. PMID 33078867.
“Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study”. BMJ (Clinical Research Ed.) 322 (7293): 1019–23. (2001). doi:10.1136/bmj.322.7293.1019. PMC 31037. PMID 11325764.
Alenghat, Francis J.; Davis, Andrew M. (2019). “Management of Blood Cholesterol”. JAMA 321 (8): 800–801. doi:10.1001/jama.2019.0015. ISSN 0098-7484. PMC 6679800. PMID 30715135.
“Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial”. Lancet 383 (9911): 60–8. (January 2014). doi:10.1016/S0140-6736(13)61914-5. PMC 4387547. PMID 24094767.
“PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide”. Biochem. Biophys. Res. Commun. 375 (1): 69–73. (October 2008). doi:10.1016/j.bbrc.2008.07.106. PMID 18675252.
Deb, Sumitra, ed (2010). “A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo”. PLOS ONE 5 (5): e10682. Bibcode: 2010PLoSO...510682G. doi:10.1371/journal.pone.0010682. PMC 2871785. PMID 20498851.
“PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates”. Mol. Ther. 20 (2): 376–81. (February 2012). doi:10.1038/mt.2011.260. PMC 3277239. PMID 22108858.
“Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates”. Proc. Natl. Acad. Sci. U.S.A. 105 (33): 11915–20. (August 2008). Bibcode: 2008PNAS..10511915F. doi:10.1073/pnas.0805434105. PMC 2575310. PMID 18695239.
Musunuru, Kiran (May 2021). “In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates” (英語). Nature 593 (7859): 429–434. Bibcode: 2021Natur.593..429M. doi:10.1038/s41586-021-03534-y. ISSN 1476-4687. PMID 34012082 13 June 2021閲覧。.
“A cholesterol-lowering VLP vaccine that targets PCSK9”. Vaccine 33 (43): 5747–55. (October 2015). doi:10.1016/j.vaccine.2015.09.044. PMC 4609631. PMID 26413878.
“Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway”. The Journal of Biological Chemistry 290 (7): 4047–58. (February 2015). doi:10.1074/jbc.M114.597229. PMC 4326815. PMID 25540198.
“The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials”. Planta Medica 79 (6): 437–46. (April 2013). doi:10.1055/s-0032-1328321. PMID 23512497.
“Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation”. PLOS ONE 7 (7): e41865. (2012). Bibcode: 2012PLoSO...741865S. doi:10.1371/journal.pone.0041865. PMC 3407131. PMID 22848640.

fiercebiotech.com

“Bristol-Myers Squibb selects Isis drug targeting PCSK9 as development candidate for prevention and treatment of cardiovascular disease”. Press Release. FierceBiotech (2008年4月8日). 2010年9月18日閲覧。
Carroll, John (7 March 2014). “Regeneron, Sanofi and Amgen shares suffer on FDA's frets about PCSK9 class”. FierceBiotech. 2022年1月27日閲覧。

futurism.com

“Scientists Gene-Hacked Monkeys to Fix Their Cholesterol”. Futurism 13 June 2021閲覧。

harvard.edu

ui.adsabs.harvard.edu

medscape.com

“Medscape”. medscape.com. 2019年5月18日閲覧。

nature.com

Musunuru, Kiran (May 2021). “In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates” (英語). Nature 593 (7859): 429–434. Bibcode: 2021Natur.593..429M. doi:10.1038/s41586-021-03534-y. ISSN 1476-4687. PMID 34012082 13 June 2021閲覧。.

nih.gov

pubmed.ncbi.nlm.nih.gov

“PCSK9 Inhibitors: Economics and Policy”. Journal of the American College of Cardiology 70 (21): 2677–2687. (2017). doi:10.1016/j.jacc.2017.10.001. PMID 29169476.
“Biology of PCSK9: beyond LDL cholesterol lowering”. Cardiovascular Research 112 (1): 429–42. (August 2016). doi:10.1093/cvr/cvw194. PMC 5031950. PMID 27496869.
“Sequence variations in PCSK9, low LDL, and protection against coronary heart disease”. The New England Journal of Medicine 354 (12): 1264–72. (March 2006). doi:10.1056/NEJMoa054013. PMID 16554528.
“Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia”. Drug News Perspect. 21 (6): 323–30. (2008). doi:10.1358/dnp.2008.21.6.1246795. PMID 18836590.
“Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels”. Proc. Natl. Acad. Sci. U.S.A. 106 (24): 9546–7. (June 2009). Bibcode: 2009PNAS..106.9546S. doi:10.1073/pnas.0904560106. PMC 2701045. PMID 19506257.
“Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels”. J. Biol. Chem. 283 (46): 31791–801. (November 2008). doi:10.1074/jbc.M805971200. PMID 18799458.
Fitzgerald, Kevin; White, Suellen; Borodovsky, Anna; Bettencourt, Brian R.; Strahs, Andrew; Clausen, Valerie; Wijngaard, Peter; Horton, Jay D. et al. (2017). “A Highly Durable RNAi Therapeutic Inhibitor of PCSK9”. New England Journal of Medicine 376 (1): 41–51. doi:10.1056/NEJMoa1609243. ISSN 0028-4793. PMC 5778873. PMID 27959715.
“Phase 3 data for PCSK9 inhibitor wows”. Nature Biotechnology 31 (12): 1057–8. (December 2013). doi:10.1038/nbt1213-1057. PMID 24316621.
“New therapies for reducing low-density lipoprotein cholesterol”. Endocrinology and Metabolism Clinics of North America 43 (4): 1007–33. (December 2014). doi:10.1016/j.ecl.2014.08.008. PMID 25432394.
“PCSK9 inhibition: the next statin?”. Journal of the American College of Cardiology 59 (25): 2354–5. (June 2012). doi:10.1016/j.jacc.2012.03.011. PMID 22465426.
“Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis”. Annals of Internal Medicine 163 (1): 40–51. (July 2015). doi:10.7326/M14-2957. PMID 25915661.
“Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data”. Current Treatment Options in Cardiovascular Medicine 19 (8): 58. (August 2017). doi:10.1007/s11936-017-0556-0. PMID 28639183.
Schmidt, Amand F.; Carter, John-Paul L.; Pearce, Lucy S.; Wilkins, John T.; Overington, John P.; Hingorani, Aroon D.; Casas, J. P. (October 20, 2020). “PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease”. The Cochrane Database of Systematic Reviews 10 (12): CD011748. doi:10.1002/14651858.CD011748.pub3. ISSN 1469-493X. PMC 8094613. PMID 33078867.
“Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study”. BMJ (Clinical Research Ed.) 322 (7293): 1019–23. (2001). doi:10.1136/bmj.322.7293.1019. PMC 31037. PMID 11325764.
Alenghat, Francis J.; Davis, Andrew M. (2019). “Management of Blood Cholesterol”. JAMA 321 (8): 800–801. doi:10.1001/jama.2019.0015. ISSN 0098-7484. PMC 6679800. PMID 30715135.
“Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial”. Lancet 383 (9911): 60–8. (January 2014). doi:10.1016/S0140-6736(13)61914-5. PMC 4387547. PMID 24094767.
“PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide”. Biochem. Biophys. Res. Commun. 375 (1): 69–73. (October 2008). doi:10.1016/j.bbrc.2008.07.106. PMID 18675252.
Deb, Sumitra, ed (2010). “A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo”. PLOS ONE 5 (5): e10682. Bibcode: 2010PLoSO...510682G. doi:10.1371/journal.pone.0010682. PMC 2871785. PMID 20498851.
“PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates”. Mol. Ther. 20 (2): 376–81. (February 2012). doi:10.1038/mt.2011.260. PMC 3277239. PMID 22108858.
“Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates”. Proc. Natl. Acad. Sci. U.S.A. 105 (33): 11915–20. (August 2008). Bibcode: 2008PNAS..10511915F. doi:10.1073/pnas.0805434105. PMC 2575310. PMID 18695239.
Musunuru, Kiran (May 2021). “In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates” (英語). Nature 593 (7859): 429–434. Bibcode: 2021Natur.593..429M. doi:10.1038/s41586-021-03534-y. ISSN 1476-4687. PMID 34012082 13 June 2021閲覧。.
“A cholesterol-lowering VLP vaccine that targets PCSK9”. Vaccine 33 (43): 5747–55. (October 2015). doi:10.1016/j.vaccine.2015.09.044. PMC 4609631. PMID 26413878.
“Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway”. The Journal of Biological Chemistry 290 (7): 4047–58. (February 2015). doi:10.1074/jbc.M114.597229. PMC 4326815. PMID 25540198.
“The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials”. Planta Medica 79 (6): 437–46. (April 2013). doi:10.1055/s-0032-1328321. PMID 23512497.
“Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation”. PLOS ONE 7 (7): e41865. (2012). Bibcode: 2012PLoSO...741865S. doi:10.1371/journal.pone.0041865. PMC 3407131. PMID 22848640.

pmc.ncbi.nlm.nih.gov

“Biology of PCSK9: beyond LDL cholesterol lowering”. Cardiovascular Research 112 (1): 429–42. (August 2016). doi:10.1093/cvr/cvw194. PMC 5031950. PMID 27496869.
“Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels”. Proc. Natl. Acad. Sci. U.S.A. 106 (24): 9546–7. (June 2009). Bibcode: 2009PNAS..106.9546S. doi:10.1073/pnas.0904560106. PMC 2701045. PMID 19506257.
Fitzgerald, Kevin; White, Suellen; Borodovsky, Anna; Bettencourt, Brian R.; Strahs, Andrew; Clausen, Valerie; Wijngaard, Peter; Horton, Jay D. et al. (2017). “A Highly Durable RNAi Therapeutic Inhibitor of PCSK9”. New England Journal of Medicine 376 (1): 41–51. doi:10.1056/NEJMoa1609243. ISSN 0028-4793. PMC 5778873. PMID 27959715.
Schmidt, Amand F.; Carter, John-Paul L.; Pearce, Lucy S.; Wilkins, John T.; Overington, John P.; Hingorani, Aroon D.; Casas, J. P. (October 20, 2020). “PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease”. The Cochrane Database of Systematic Reviews 10 (12): CD011748. doi:10.1002/14651858.CD011748.pub3. ISSN 1469-493X. PMC 8094613. PMID 33078867.
“Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study”. BMJ (Clinical Research Ed.) 322 (7293): 1019–23. (2001). doi:10.1136/bmj.322.7293.1019. PMC 31037. PMID 11325764.
Alenghat, Francis J.; Davis, Andrew M. (2019). “Management of Blood Cholesterol”. JAMA 321 (8): 800–801. doi:10.1001/jama.2019.0015. ISSN 0098-7484. PMC 6679800. PMID 30715135.
“Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial”. Lancet 383 (9911): 60–8. (January 2014). doi:10.1016/S0140-6736(13)61914-5. PMC 4387547. PMID 24094767.
Deb, Sumitra, ed (2010). “A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo”. PLOS ONE 5 (5): e10682. Bibcode: 2010PLoSO...510682G. doi:10.1371/journal.pone.0010682. PMC 2871785. PMID 20498851.
“PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates”. Mol. Ther. 20 (2): 376–81. (February 2012). doi:10.1038/mt.2011.260. PMC 3277239. PMID 22108858.
“Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates”. Proc. Natl. Acad. Sci. U.S.A. 105 (33): 11915–20. (August 2008). Bibcode: 2008PNAS..10511915F. doi:10.1073/pnas.0805434105. PMC 2575310. PMID 18695239.
“A cholesterol-lowering VLP vaccine that targets PCSK9”. Vaccine 33 (43): 5747–55. (October 2015). doi:10.1016/j.vaccine.2015.09.044. PMC 4609631. PMID 26413878.
“Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway”. The Journal of Biological Chemistry 290 (7): 4047–58. (February 2015). doi:10.1074/jbc.M114.597229. PMC 4326815. PMID 25540198.
“Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation”. PLOS ONE 7 (7): e41865. (2012). Bibcode: 2012PLoSO...741865S. doi:10.1371/journal.pone.0041865. PMC 3407131. PMID 22848640.

ncbi.nlm.nih.gov

nytimes.com

Gina Kolata, "These Cholesterol-Reducers May Save Lives. So Why Aren’t Heart Patients Getting Them?", The New York Times, Oct. 2, 2018. Retrieved 5 October 2018.

pfizer.com

“Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor”. 2022年1月27日閲覧。

worldcat.org

search.worldcat.org

Fitzgerald, Kevin; White, Suellen; Borodovsky, Anna; Bettencourt, Brian R.; Strahs, Andrew; Clausen, Valerie; Wijngaard, Peter; Horton, Jay D. et al. (2017). “A Highly Durable RNAi Therapeutic Inhibitor of PCSK9”. New England Journal of Medicine 376 (1): 41–51. doi:10.1056/NEJMoa1609243. ISSN 0028-4793. PMC 5778873. PMID 27959715.
Schmidt, Amand F.; Carter, John-Paul L.; Pearce, Lucy S.; Wilkins, John T.; Overington, John P.; Hingorani, Aroon D.; Casas, J. P. (October 20, 2020). “PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease”. The Cochrane Database of Systematic Reviews 10 (12): CD011748. doi:10.1002/14651858.CD011748.pub3. ISSN 1469-493X. PMC 8094613. PMID 33078867.
Alenghat, Francis J.; Davis, Andrew M. (2019). “Management of Blood Cholesterol”. JAMA 321 (8): 800–801. doi:10.1001/jama.2019.0015. ISSN 0098-7484. PMC 6679800. PMID 30715135.
Musunuru, Kiran (May 2021). “In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates” (英語). Nature 593 (7859): 429–434. Bibcode: 2021Natur.593..429M. doi:10.1038/s41586-021-03534-y. ISSN 1476-4687. PMID 34012082 13 June 2021閲覧。.